Shengxin lithium energy: the design capacity of sabixing Lithium Tantalum mine project is expected to be 900000 tons / year of ore processing capacity
Shengxin lithium energy said on the investor interaction platform that according to the company's preliminary planning, the designed capacity scale of sabixing Lithium Tantalum mine project is expected to be 900000 tons / year of ore processing capacity and about 200000 tons of lithium concentrate per year. It is expected that the mine will be completed and put into operation by the end of 2022 or the beginning of 2023. The above is only the preliminary plan of the company according to the current situation. If there is any important progress in the follow-up, the company will timely perform the obligation of information disclosure according to relevant regulations.
This text is a result of machine translation.
Related companies：
Briefing Jun 10, 2022 09:48 PM
Singaporean Prime Minister Lee Hsien Loong meets with weifenghe
In-depth
Briefing Jun 10, 2022 07:17 PM
Baiji Shenzhou PD-1 monoclonal antibody baizean ® The ninth indication was obtained and the first-line treatment for nasopharyngeal carcinoma was approved
Briefing Apr 28, 2022 09:59 AM
A new breakthrough in the first-line treatment of advanced esophageal cancer: PD-1 monoclonal antibody baizean ® Global phase 3 clinical trials reached the primary end point
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Briefing Mar 11, 2022 10:59 AM
· Financials
Baiji China: the tentative list is a normal step and will not affect the listing of the company on NASDAQ
Briefing Feb 25, 2022 08:48 PM
Ministry of agriculture and rural areas: implement the ten-year fishing ban on the Yangtze River in 2022 and promote the conservation of aquatic biological resources
Briefing Feb 15, 2022 06:19 AM
· Automotive
Hillhouse Q4 position: increased holdings of ideal automobile and Xiaopeng automobile sea, and ideal automobile rushed into the top ten
Briefing Jan 31, 2022 10:29 AM
· Healthcare
Hong Kong Pharmaceutical stocks generally rose, with Cinda biology up nearly 6%
Briefing Jan 05, 2022 11:24 AM
· Healthcare
54% off! Pamipali, the first PARP inhibitor approved for the treatment of platinum sensitive and platinum resistant recurrent ovarian cancer, was included in Medicare
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Apr 23, 2024 02:21 PM